(Q33357164)

26 July 2017

1 reference

title

Myelofibrosis with myeloid metaplasia (English)

1 reference

26 July 2017

1 reference

Giovanni Barosi

1

1 reference

26 July 2017

publication date

1 October 2003

1 reference

Hematology / Oncology Clinics of North America

26 July 2017

published in

1 reference

26 July 2017

volume

17

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1211-1226

1 reference

Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Age and sex distributions of hematological malignancies in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Idiopathic myelofibrosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Prognostic factors in idiopathic (primary) osteomyelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Idiopathic myelofibrosis (agnogenic myeloid metaplasia): clinicopathological analysis of 32 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Acute cardiac tamponade associated with pericardial extramedullary hematopoiesis in agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Cutaneous extramedullary hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Spinal cord compression due to extramedullary haemopoiesis in myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Unexplained pulmonary hypertension in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Coombs' positive hemolytic anemia in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Lupus anticoagulant in myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Immune Complexes in Myelofibrosis: a Possible Guide to Management

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet's syndrome associated with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Skin manifestation of agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Erythropoiesis in Myelofibrosis with Myeloid Metaplasia: Recognition of Different Classes of Patients by Erythrokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Transitional Myeloproliferative Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Early-stage idiopathic (primary) myelofibrosis--current issues of diagnostic features

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

A clinical and pathological study of seventy cases of myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

c-kit point mutation of extracellular domain in patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Idiopathic myelofibrosis: anaemia may respond to low-dose dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Management of myelofibrosis with intermittent hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Reversal of myelofibrosis by hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

A prognostic classification of myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Anagrelide, a selective thrombocytopenic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900080-7

7 January 2021

10.1016/S0889-8588(03)00080-7

Identifiers

DOI

1 reference

26 July 2017

1 reference